Ultragenyx Pharmaceutical is a mid-cap biotech firm with a promising pipeline and an optimistic outlook from analysts. Click ...

Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the ...

Crysvita, an antibody targeting fibroblast growth factor 23, is approved in the United States for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients. Crysvita ...

Burosumab-twza or KRN23 is a monoclonal antibody prescribed to treat a rare hereditary disorder called X-linked hypophosphatemia (low levels of phosphate in the blood) in adult and pediatric ...